Development of *** Targeted New Drug Lead Compounds Activating IFN-γ for Immune Checkpoint Inhibitor Resistant Cancers**

Gwangju Institute of Science & Technology



ONCOLOGY	Hit
Product Type	Chemical - Small Molecule
Indication	Refractory cancers to conventional immune checkpoint inhibitors
Target	-
MoA(Mechanism of Action)	Activation of Interferon gamma signaling in cancer cells by inhibition of the target
Competitiveness	First in Class (Novel Target)
Development Stage	Hit
Route of Administration	Oral administration